135334-75-7 Suppliers

Recommended suppliers

135334-75-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 135334-75-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,5,3,3 and 4 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 135334-75:
(8*1)+(7*3)+(6*5)+(5*3)+(4*3)+(3*4)+(2*7)+(1*5)=117
117 % 10 = 7
So 135334-75-7 is a valid CAS Registry Number.

135334-75-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name	5-(4-carboxymethoxyphenyl)-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

1.2 Other means of identification

Product number	-
Other names	5-(4-carboxymethoxyphenyl)-6-methyl-2-oxo-1,2,dihydro-3-pyridinecarbonitrile

1.3 Recommended use of the chemical and restrictions on use

Identified uses	For industry use only.
Uses advised against	no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number	-
Service hours	Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:135334-75-7 SDS

135334-75-7Upstream product

135334-75-7Downstream Products

135334-75-7Relevant academic research and scientific papers

CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE

-

Page/Page column 74-76, (2010/11/08)

The present invention provides compounds possessing inhibitory activity against ? adrenergic receptors and phosphodiesterase (PDE), including type 3 phosphodiesterase (PDE-3). The present invention further provides pharmaceutical compositions comprising s

COMPOUNDS WITH PHOSPHODIESTERASE INHIBITING AND CALCIUM CHANNEL BLOCKING ACTIVITIES

-

Page/Page column 33-34, (2010/02/11)

The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.

DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY

-

Page 36; 39, (2010/02/06)

COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE

-

Page 51, (2010/02/07)

This invention provides compounds that possess inhibitory activity against β--adrenergic receptors and phosphodiesterase PDE, including phosphodiesterase 3 (PDE3 ). This invention further provides pharmaceutical compositions comprising such -compounds; methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine; and methods of preparing pharmaceutical compositions and compounds that possess inhibitory activity against ?-adrenergic receptors and PDE.

PYRIDONE NITRILES USEFUL IN TREATING CARDIOVASCULAR DISEASE

-

, (2008/06/13)

Pyridones of formula (I) for treating congestive heart failure: STR1 wherein: R 1 and R 2 are a variety of phenyl substituents, L is a divalent alkylene or amide containing alkylene linking group. Pharmaceutical composition, methods for their use in treat

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 135334-75-7

135334-75-7

Basic information

Chemical Properties

Safety Data